Oxford Nanopore Technologies’ recent growth surge has reinvigorated analyst and manager outlooks for the company, despite the fact it may take years for it to break even.
In an H1 2023 trading update last week, the biotech company - a stock once best known as a holding of Neil Woodford - reported £86m in revenue for the period, representing 22% year-on-year growth on a reported basis, and 16% on a constant currency basis. Stock Spotlight: YouGov GfK deal a 'shrewd' business move Full year revenue was expected to fall between 16-30% on a constant currency basis, with CEO and co-founder Gordon Sanghera noting "demand for our technology continues to grow from an increasingly broad and diverse base of customers". He continued: "We have also made conside...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
